Drägerwerk AG (DRW8) Fair Value & Analysis
Healthcare · DE · Market cap €1.4B
Fair value as of: Jun 24, 2026
From 25 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from €238.41 to €286.11 (+20.0%) since Jun 23, 2026. Share price −2.2% over the past month.
Price vs Fair Value (12 months)
12‑month range €48.75 – €73.99 · fair‑value band €190.23 – €380.12 · the €70.40 price screens below the €286.11 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Drägerwerk AG (DRW8) currently trades at €70.40, while our model-based Fair Value estimate is €286.11 — implying the stock looks roughly 306.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Drägerwerk AG generated revenue of €3.5B at a net margin of 4.4%. Revenue grew 3.5% year over year. It earns a return on equity of 9.6%. Net debt stands at €123M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. In addition, it offers patient monitoring systems; anaesthesia machines; medical ventilators and lung monitoring; neonatal incubators and thermoregulation; phototherapy lights and bilirubinometers; surgical and examination lights; medical pendants and infrastructure design; medical gas pipeline system in hospitals; and hospital consumables and accessories, as well as hospital planning and design services. F…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Drägerwerk AG reported revenue of €3.5B in FY2025 versus €3.3B in FY2021, a compound +1.1%/yr. Reported net income was €139M in FY2025, compounding −2.5%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$37.76 | R$6.34 | -83% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Drägerwerk AG (DRW8) undervalued?
What is the fair value of DRW8?
What is the quality score of DRW8?
What is the revenue of Drägerwerk AG (DRW8)?
What is the net profit margin of DRW8?
Does Drägerwerk AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.